- · Sources have said that the concerned authorities have failed to discover any curative effects of the medicines against Covid-19
- · Earlier AIIMS have clarified the inability of Ivermectin to curtail the duration of symptoms of the viral load with Covid patients
- · The reason for taking down HCQ was its incapacity to provide mortality benefits
Today, the names of Ivermectin and Hydroxychloroquine (HCQ) have been pulled off by the Indian Council of Medical Research from their revised “clinical guidelines for the management of adult Covid-19 patients.”
According to sources, no concrete curative effect of the medicines against Covid-19 was discovered by the concerned authorities. Earlier, a review by the All India Institute of Medical Sciences (AIIMS) had clarified that even at inflated doses Ivermectin failed to reduce the duration of symptoms of the viral load within patients affected by Covid-19.
The clarifications of AIIMS were confirmed by a trial that was conducted on 157 patients admitted to the hospital with mild to moderate infection during the uproar of the first wave between July and September 2020.
However, Hydroxychloroquine (HCQ) was taken off from the guidelines because it failed to provide any mortality benefit. It also instigated the possibilities of address drug effect (ADE) when co-regulated with Azithromycin. Ahead of the health minister of Goa Mr. Vishwajit Rane advocating the dosage of Ivermectin for all adult residents of the state, the World Health Organization has warned about its usage.